David I. Quinn, MD: Prostate Cancer Update ASCO 2012

Dr. David Quinn brings us a prostate cancer data update from ASCO 2012.

We forgot to ask Dr. Quinn his opinion on PSA testing.  He emailed us the following statement:

The US Preventative Taskforce is making statement about what the nation should invest in.   Individuals need to make their own informed decisions and this process is well supported on the American Cancer Society website.  We have screened a population that is too old and detected disease that is too slow growing to detect a larger survival benefit – in the European study we need to screen and treat between 25 and 50 men to save a life from prostate cancer.
If we screen a young population then based on the Malmö Preventive Medicine Study data we will get better returns. We also need to focus on high groups with family history and African American men.

This interview was filmed at the American Society of Clinical Oncology Annual Meeting in Chicago 2012.

David Ian Quinn MBBS Honors Class I, PhD, FRACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, leader of the Developmental Therapeutics Program for the USC Norris Comprehensive Cancer Center, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC.

The Group Room at the American Society of Clinical Oncology (ASCO) Annual Meeting 2012 was made possible, in part, by: